How immune cells interact with bile duct cells in alcoholic liver disease
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
This study looks at how certain immune cells interact with liver cells in people with alcoholic hepatitis to better understand liver damage and find new ways to treat the condition, which could help patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10878956 on NIH RePORTER |
What this research studies
This research investigates the interactions between immune cells called neutrophils and bile duct cells, known as cholangiocytes, in the context of alcoholic hepatitis. It aims to understand how these interactions contribute to liver injury and cholestasis, a condition where bile flow is impaired. By exploring the mechanisms behind cholangiocyte dysfunction, the study seeks to identify potential new therapeutic targets for treating alcoholic hepatitis. Patients may benefit from insights gained into the disease's progression and new treatment options that could arise from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with alcoholic hepatitis who are experiencing cholestasis.
Not a fit: Patients with alcoholic hepatitis who do not exhibit cholestasis or have other unrelated liver conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients suffering from alcoholic hepatitis, potentially reducing mortality rates.
How similar studies have performed: Previous research has shown that understanding the role of cholangiocytes in liver diseases can lead to significant advancements in treatment, suggesting that this approach has potential for success.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Nathanson, Michael H — Yale University
- Study coordinator: Nathanson, Michael H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.